Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and new treatment approaches are urgently needed. Immunotherapy has emerged as a safe and effective treatment for certain solid tumors, however the development of effective immunotherapies for AML requires a better understanding of the mechanisms by which leukemia evades the immune system. AML is associated with selective dysregulation of antigen presenting cells (APCs), which are a vital component of anti-tumor immune responses. The study will investigate mechanisms by which leukemia cells interfere with APC development with the goal of identifying novel immunotherapeutic targets in AML.